Details for Patent: 12,485,111

Which drugs does patent 12,485,111 protect, and when does it expire?

Patent 12,485,111 protects METAXALONE and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 12,485,111

Title:	Reduced dose metaxalone formulations
Abstract:	Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.
Inventor(s):	Mukteeshwar Gande, Robert M. Levy
Assignee:	PRIMUS PHARMACEUTICALS Inc
Application Number:	US18/409,208
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 12,485,111

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Primus Pharms	METAXALONE	metaxalone	TABLET;ORAL	022503-001	Jun 1, 2015		RX	Yes	Yes	12,485,111		Y			METAXALONE IS INDICATED AS AN ADJUNCT TO REST, PHYSICAL THERAPY, AND OTHER MEASURES FOR THE RELIEF AND DISCOMFORT ASSOCIATED WITH ACUTE, PAINFUL MUSCULOSKELETAL CONDITIONS

International Family Members for US Patent 12,485,111

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020307390
Brazil	112021026371
European Patent Office	3989946